This document defines delirium and discusses its prevalence, risk factors, pathophysiology, clinical presentations, assessment tools, and management strategies. Delirium is an acute confusional state characterized by fluctuating mental status and inattention. It has a prevalence of 20-80% in hospitals and increases mortality risk by 10% per day. Hypoactive delirium is most common. Assessment tools include CAM-ICU and ICDSC. Management prioritizes non-pharmacological strategies like ABCDE bundles and uses anti-psychotics like haloperidol for pharmacological treatment.
This presentation gives detailed description of symptoms of catatonia with its etiologies and differential diagnoses. It should help to differentiate catatonia in neurological and psychiatric disorders.
Delirium, also referred to as "acute confusional state" or "acute brain syndrome," is a condition of severe confusion and rapid changes in brain function.
This presentation gives detailed description of symptoms of catatonia with its etiologies and differential diagnoses. It should help to differentiate catatonia in neurological and psychiatric disorders.
Delirium, also referred to as "acute confusional state" or "acute brain syndrome," is a condition of severe confusion and rapid changes in brain function.
hii guys this is my ongoing presentation from my speciality class i hope u guys lije that please so i hope it is been useful for u in ur specialities by getting little help with that
Dementia is a broad term which describes symptoms affecting memory, thinking ability that creates hindrance in performing daily activities. Two important brain functions are badly hit namely- memory and judgement.
Neurocognitive disorders includes : Delirium and Dementia.
This presentation focuses on causes, risk factors, management and how to prevent its complication
hii guys this is my ongoing presentation from my speciality class i hope u guys lije that please so i hope it is been useful for u in ur specialities by getting little help with that
Dementia is a broad term which describes symptoms affecting memory, thinking ability that creates hindrance in performing daily activities. Two important brain functions are badly hit namely- memory and judgement.
Neurocognitive disorders includes : Delirium and Dementia.
This presentation focuses on causes, risk factors, management and how to prevent its complication
Delirium is a syndrome not a disease and it has many causes. it is an acute organic mental disorder characterised by impairment of consciousness, disorientation and disturbances in perception and restlessness.
Delirium is an organic cerebral syndrome characterized by concurrent disturbances of consciousness and attention, perception, thinking, memory, psychomotor behavior, emotion and sleep wake schedule.
Delirium Tremens is a psychotic condition caused by complications from alcohol withdrawal. It involves tremors, hallucination, anxiety and disorientation.
The word delirium means “out of one’s furrow” which refers to the dramatic behavior changes that the person may experience. Some have called delirium "brain failure” because it may represent a variety of caused such as heart failure does in cardiac health.
Delirium is an outcome of a general medical condition, head injury and drug intoxication or withdrawal.
Knee anatomy and clinical tests 2024.pdfvimalpl1234
This includes all relevant anatomy and clinical tests compiled from standard textbooks, Campbell,netter etc..It is comprehensive and best suited for orthopaedicians and orthopaedic residents.
Ethanol (CH3CH2OH), or beverage alcohol, is a two-carbon alcohol
that is rapidly distributed in the body and brain. Ethanol alters many
neurochemical systems and has rewarding and addictive properties. It
is the oldest recreational drug and likely contributes to more morbidity,
mortality, and public health costs than all illicit drugs combined. The
5th edition of the Diagnostic and Statistical Manual of Mental Disorders
(DSM-5) integrates alcohol abuse and alcohol dependence into a single
disorder called alcohol use disorder (AUD), with mild, moderate,
and severe subclassifications (American Psychiatric Association, 2013).
In the DSM-5, all types of substance abuse and dependence have been
combined into a single substance use disorder (SUD) on a continuum
from mild to severe. A diagnosis of AUD requires that at least two of
the 11 DSM-5 behaviors be present within a 12-month period (mild
AUD: 2–3 criteria; moderate AUD: 4–5 criteria; severe AUD: 6–11 criteria).
The four main behavioral effects of AUD are impaired control over
drinking, negative social consequences, risky use, and altered physiological
effects (tolerance, withdrawal). This chapter presents an overview
of the prevalence and harmful consequences of AUD in the U.S.,
the systemic nature of the disease, neurocircuitry and stages of AUD,
comorbidities, fetal alcohol spectrum disorders, genetic risk factors, and
pharmacotherapies for AUD.
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...VarunMahajani
Disruption of blood supply to lung alveoli due to blockage of one or more pulmonary blood vessels is called as Pulmonary thromboembolism. In this presentation we will discuss its causes, types and its management in depth.
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...kevinkariuki227
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?bkling
Are you curious about what’s new in cervical cancer research or unsure what the findings mean? Join Dr. Emily Ko, a gynecologic oncologist at Penn Medicine, to learn about the latest updates from the Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women’s Cancer. Dr. Ko will discuss what the research presented at the conference means for you and answer your questions about the new developments.
New Drug Discovery and Development .....NEHA GUPTA
The "New Drug Discovery and Development" process involves the identification, design, testing, and manufacturing of novel pharmaceutical compounds with the aim of introducing new and improved treatments for various medical conditions. This comprehensive endeavor encompasses various stages, including target identification, preclinical studies, clinical trials, regulatory approval, and post-market surveillance. It involves multidisciplinary collaboration among scientists, researchers, clinicians, regulatory experts, and pharmaceutical companies to bring innovative therapies to market and address unmet medical needs.
NVBDCP.pptx Nation vector borne disease control programSapna Thakur
NVBDCP was launched in 2003-2004 . Vector-Borne Disease: Disease that results from an infection transmitted to humans and other animals by blood-feeding arthropods, such as mosquitoes, ticks, and fleas. Examples of vector-borne diseases include Dengue fever, West Nile Virus, Lyme disease, and malaria.
Explore natural remedies for syphilis treatment in Singapore. Discover alternative therapies, herbal remedies, and lifestyle changes that may complement conventional treatments. Learn about holistic approaches to managing syphilis symptoms and supporting overall health.
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
2. • defined as follows: (1) A disturbance of consciousness (i.e.,
reduced clarity of awareness of the environment) with
reduced ability to focus, sustain, or shift attention. (2) A
change in cognition (e.g., memory deficit, disorientation,
language disturbance) (3) The disturbance develops over a
short period (usually hours to days) and tends to fluctuate
during the course of the day.
One group found that neurology/neurosurgical patients were
at the highest risk, followed by trauma patients, and then
medical intensive care patients. Surgical ICU patients were at
the lowest risk.
3. • Defined by Diagnostic and Statistical Manual
of Mental Disorders(DSM)-IV.
• Delirium is described in the DSM IV-TR as an
acute confusional state characterized by
fluctuating mental status, inattention, and
either altered level of consciousness or
disorganized thinking.
4.
5. • prevalence of 20% to 80%,
• Each aditional day with delirium increases a
patient’s risk of dying by 10%.
• In one large study, mixed delirium was found
to be the mostcommon subset (54.9%), with
hypoactive somewhat less common (43.5%),
and hyperactive agitated delirium was rare
(1.6%)
6. • Delirium can be classified according to
psychomotor behavior into hypoactive delirium,
hyperactive delirium, or a mixed subtype.
Hypoactive delirium, which is the most prevalent
form of delirium, is characterized by decreased
physical and mental activity and inattention. In
contrast, hyperactive delirium is characterized by
combativeness and agitation.
• Hypoactive delirium might actually be associated
with a worse prognosis.
11. PATHOPHYSIOLOGY
• is poorly understood
• Neurotransmitter imbalance. Multiple
neurotransmitters have been implicated, including
dopamine (excess), acetylcholine (relative
depletion), γ-aminobutyric acid (GABA), serotonin,
endorphins, norepinephrine, and glutamate.
• Inflammatory mediators. Inflammatory mediators, such
as tumor necrosis factor alpha (TNF-α), interleukin-1
(IL-1), have been implicated in the pathogenesis of
endothelial damage, thrombin formation, and
microvascular dysfunction in the central nervous
system (CNS), contributing to delirium.
12.
13. CLINICAL PRESENTATIONS OF
DELIRIUM
• Fluctuating levels of arousal over the day’s
course is a central hallmark of delirium and a
major diagnostic criterion.
• psychomotor agitation syndrome usually
occurs during the night hours, it has been
termed the sundown syndrome and is virtually
diagnostic of stress-induced delirium.
14.
15. ASSESSMENT
• many scales available for the assessment of
agitation and sedation
1. the Riker Sedation-Agitation scale [ SAS]
2. the Motor Activity Assessment Scale (MAAS)
3. Richmond Agitation-Sedation Scale (RASS)
4. the Adaptation to Intensive care environment
( ATICE)
5. The Minnesota Sedation Assessment Tool
(MSAT).
16.
17.
18. • A number of tools have been developed to aid in
the detection of delirium in the ICU. These tools
have been validated for use in both intubated and
nonintubated patients and measured against a
“gold standard,” the Diagnostic and Statistical
Manual of Mental Disorders (DSM) criteria. The
tools are the Confusion Assessment Method for
the ICU (CAM-ICU) and the Intensive Care
Delirium Screening Checklist (ICDSC).
• A meta-analysis of studies involving these
methods demonstrates a higher sensitivity and
specificity for the CAM-ICU.
19. CAM-ICU
• To perform the CAM-ICU,
patients are first evaluated
for level of consciousness;
patients who respond to
verbal commands (a RASS
score of −3 or higher level
of arousal) can then be
assessed for delirium. The
CAM-ICU comprises four
features: (1) a change in
mental status from
baseline or a fluctuation in
mental status, (2)
inattention, (3)
disorganized thinking, and
(4) altered level of
consciousness.
20. ICDSC
• A score of 4 or above
indicates delirium,
while 0 indicates no
delirium. Patients with
scores between 1 and
3 are considered to
have subsyndromal
delirium,
• which has worse
prognostic
implications than the
absence of delirium
but a better prognosis
than clearly present
delirium.
25. • The use of ABCDEs (Awakening and Breathing
Trials, Choice of appropriate sedation,
Delirium monitoring and management, and
Early mobility and Exercise) has been shown
to decrease the incidence of delirium and
improve patient outcome.
• IWATCHDEATH and DELIRIUM mnemonics can
be particularly helpful in guiding this initial
evaluation.
26. Pharmacological Treatment of
Delirium
• Anti-Psychotics : Haloperidol (used by 75–80% of
intensivists) and atypical anti-psychotics (used by
35–40% of intensivists) have emerged as the
standard pharmacological treatments for delirium
in the ICU.
• The main mechanisms of action of
haloperidol are thought to be antagonism at
cortical dopamine (D2) receptors [78–81],
nigrostriatal pathway D2 blockade, and
disinhibition of acetylcholine (i.e.,
acetylcholine increase)
27. • haloperidol binds with a high affinity at D2
receptors, relatively low affinity at D1 receptors,
and it exhibits little adrenergic or muscarinic
activity compared to lower potency neuroleptics.
• Haloperidol is administered intravenously or
intramuscularly in the critical care setting [86].
Both methods have high bioavailability (~100%).
the mean half-life of haloperidol is 21 hours. It is
extensively metabolized by the liver.
• Common doses for ICU patients range from 4 to
20 mg/day
28. • Atypical Anti-Psychotics : typical anti-psychotics may be
as efficacious for delirium and were associated with
less EPS or side effects compared with haloperidol and
other neuroleptic anti-psychotics .
1. Olanzapine
2. Amisulpride
3. quetiapine
4. Risperidone
• Medications should be avoided in with prolonged QT
intervals
29. Alpha-2 Agonists: Clonidine and
Dexmedetomidine
• The alpha-2 agonists, such as
dexmedetomidine, have gained popularity in
their use due to decreased respiratory
suppression and recent trials demonstrating
reduced delirium prevalence as compared
with GABA-ergic drugs (e.g., benzodiazepines).